IMUNON (IMNN) announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its ...

The ability to genetically engineer plants is largely thanks to a microscopic helper: a bacterium called Agrobacterium ...

Adapted from a news release by the Innovative Genomics Institute (IGI) at UC Berkeley.The ability to genetically engineer plants is largely thanks to ...

As previously announced, IMUNON plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in ...

Branca Bunús is a gene delivery technology company based in Ireland, specializing in the development of safe gene delivery vectors and effective transfection reagents derived from unique cationic ...

Crispr/Cas9 works by having Crispr (pieces of DNA sequences) guide Cas9 (an enzyme that can cut ... LentiGlobin (marketed under the name Lyfgenia) uses the same BB305 viral vector as Zynteglo to ...

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science ...

Here we describe two methods for generating DNA fragments with single-stranded overhangs, like those generated by the activity of many restriction enzymes, by simple methods that do not involve ...

Australian scientists have successfully used an innovative gene therapy technique in the lab to combat a key cause of vision ...

With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptanceCompany also announces FDA End-of-Phase 2 in-person meeting ...